The incidence of type I galactosemia is around 1 in every 60,000 newborns, while type II affects fewer than 1 in 100,000 newborns and type III affects fewer still. Symptoms.

Over the past 60 days, Allogene Therapeutics’ estimates for loss per share have narrowed from $1.40 to $1.35 for 2024, and ...

Galactosemia is a rare genetic condition that prevents babies from processing galactose, an important sugar in breast milk. ... Type I occurs in about 1 in every 30,000 to 60,000 people.

The US Food and Drug Administration (FDA) has declined to approve Applied Therapeutics’ govorestat for classic galactosemia, prolonging the wait for the first marketed treatment for the genetic ...

For context, 1 in every 16,000 to 48,000 births are diagnosed with galactosemia. This means we can approximate the total population with this condition in the US at about 20,830 to 6,943.

Galactosemia is a rare genetic, metabolic disorder caused by a deficiency in the galactose-1-phosphate uridyltransferase (GALT). This means patients cannot break down galactose, causing a buildup ...

The NDA included data from the phase 1/2 ACTION-Galactosemia study (ClinicalTrial.gov Identifier: NCT04117711) and the phase 3 ACTION-Galactosemia Kids trial (ClinicalTrial.gov Identifier ...

The consensus estimate for 2025 loss per share has narrowed from $1.71 to $1.14. Year to date, shares of FULC have plunged 49%. FULC’s earnings beat estimates in each of the trailing four ...

Galactosemia affects around 1 in every 60,000 infants of European origin. The condition is caused by a mutation in the gene that codes for the GALT enzyme.

Over the past 60 days, Allogene Therapeutics’ estimates for loss per share have narrowed from $1.40 to $1.35 for 2024, and that for 2025 has narrowed from $1.46 to $1.34. ALLO shares have lost ...